Sun Pharmaceutical Industries Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is TOLVAPTAN, with a corresponding US DMF Number 37952.
Remarkably, this DMF maintains an Active status since its submission on January 03, 2024, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 12, 2024, and payment made on December 29, 2023, indicating their dedication to facilitating drug approvals, Categorized as Type II